Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Open-Label Phase III Trial of MK-3475 versus Platinum based Chemotherapy in 1L Subjects with PD-L1 Strong Metastatic Non-Small Cell Lung Cancer

Next Previous
Search
Trial Profile

A Randomized Open-Label Phase III Trial of MK-3475 versus Platinum based Chemotherapy in 1L Subjects with PD-L1 Strong Metastatic Non-Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-024
  • Sponsors Merck Sharp & Dohme

    • Most Recent Events

    • 09 Nov 2022 Results evaluating the cost-effectiveness of cemiplimab versus pembrolizumab by deriving OS and PFS data from EMPOWER-Lung 1 (cemiplimab) and KEYNOTE-024 (pembrolizumab), presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 09 Nov 2022 Results analyzing the number needed to treat (NNT) and cost of preventing an event (COPE) for cemiplimab and pembrolizumab as first-line treatments for advanced non-small-cell lung cancer presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 09 Aug 2022 Results of pooled analysis of 5 studies (KEYNOTE-024, KEYNOTE-042, KEYNOTE-598, KEYNOTE-189 and KEYNOTE-407) assessing outcomes in patients who began second-course pembrolizumab monotherapy, presented at the 2022 World Conference on Lung Cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top